Filing Flows › Comparisons › IOVA vs IPSC
Iovance Biotherapeutics vs Century Therapeutics: IOVA and IPSC compared
Iovance Biotherapeutics is the larger company: $121M of revenue in its latest quarter (Q3 2026) against $109M for Century Therapeutics (Q1 2025). Century Therapeutics is growing faster (128× against +80% a year earlier). Century Therapeutics is more profitable, with an operating margin of 67.9% against -19.7%.
Where the money goes: IOVA and IPSC
Iovance Biotherapeutics (IOVA) · Q3 2026
Iovance Biotherapeutics, Q3 2026: revenue $121M (+80% year over year), operating margin -19.7%, net loss $22.3M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
Century Therapeutics (IPSC) · Q1 2025
Century Therapeutics, Q1 2025: revenue $109M (128× year over year), operating margin 67.9%, net earnings $76.6M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.
| Iovance Biotherapeutics (IOVA) | Century Therapeutics (IPSC) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q1 2025 |
| Revenue | $121M | $109M |
| Revenue growth, Y/Y | +80% | 128× |
| Operating margin | -19.7% | 67.9% |
| Net earnings | −$22.3M | $76.6M |
| Net margin | -18.3% | 70.1% |
| Operating cash flow | −$4.5M | −$34.6M |
| Market value | $6.6B | — |
| Analysts’ mean target | $14.50 | — |
Questions
Which is bigger, Iovance Biotherapeutics or Century Therapeutics?
Iovance Biotherapeutics is the larger company: $121M of revenue in its latest quarter (Q3 2026) against $109M for Century Therapeutics (Q1 2025).
Is Iovance Biotherapeutics or Century Therapeutics growing faster?
Century Therapeutics is growing faster (128× against +80% a year earlier).
Which is more profitable, Iovance Biotherapeutics or Century Therapeutics?
Century Therapeutics is more profitable, with an operating margin of 67.9% against -19.7%.
More: Iovance Biotherapeutics earnings · how Iovance Biotherapeutics makes money · Century Therapeutics earnings · how Century Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed May 15, 2025). Fiscal quarters can end on different dates. Not investment advice.